You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Phase I data at ESMO suggested that the experimental drug may be particularly effective in KRAS G12C-mutated lung and colon cancers.
The Amgen-sponsored Phase Ib study is evaluating the combination in patients with advanced solid tumors characterized by KRAS G12C mutations.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
At least one drugmaker is planning to submit for FDA approval of its KRAS inhibitor based on data from Phase I/II, single-arm trial in heavily pretreated lung cancer patients.
The institute has recommended the drug as a cost-effective use of NHS resources following submission of new evidence and reflecting a confidential price discount arrangement.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.